Price increases in the pharma sector may be considered abuse of a dominant position

by Andreas Christensen | Apr 21, 2018 | Niet gecategoriseerd

In a recent case, the Danish Competition Council ruled that CD Pharma had abused its dominant position by increasing the price on the medicinal product Syntocinon by 2,000 % in 2014. The decision is the first Danish ruling on excessive pricing in the pharmaceutical sector.
(more…)